Cancer-Causative Mutations Occurring in Early Embryogenesis.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
18
08
2021
revised:
21
11
2021
accepted:
20
12
2021
pubmed:
25
12
2021
medline:
6
4
2022
entrez:
24
12
2021
Statut:
ppublish
Résumé
Mosaic mutations in normal tissues can occur early in embryogenesis and be associated with hereditary cancer syndromes when affecting cancer susceptibility genes (CSG). Their contribution to apparently sporadic cancers is currently unknown. Analysis of paired tumor/blood sequencing data of 35,310 patients with cancer revealed 36 pathogenic mosaic variants affecting CSGs, most of which were not detected by prior clinical genetic testing. These CSG mosaic variants were consistently detected at varying variant allelic fractions in microdissected normal tissues (n = 48) from distinct embryonic lineages in all individuals tested, indicating their early embryonic origin, likely prior to gastrulation, and likely asymmetrical propagation. Tumor-specific biallelic inactivation of the CSG affected by a mosaic variant was observed in 91.7% (33/36) of cases, and tumors displayed the hallmark pathologic and/or genomic features of inactivation of the respective CSGs, establishing a causal link between CSG mosaic variants arising in early embryogenesis and the development of apparently sporadic cancers. Here, we demonstrate that mosaic variants in CSGs arising in early embryogenesis contribute to the oncogenesis of seemingly sporadic cancers. These variants can be systematically detected through the analysis of tumor/normal sequencing data, and their detection may affect therapeutic decisions as well as prophylactic measures for patients and their offspring. See related commentary by Liggett and Sankaran, p. 889. This article is highlighted in the In This Issue feature, p. 873.
Identifiants
pubmed: 34949653
pii: 2159-8290.CD-21-1110
doi: 10.1158/2159-8290.CD-21-1110
pmc: PMC8983494
mid: NIHMS1767888
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
949-957Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA247749
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2021 American Association for Cancer Research.
Références
Science. 2018 Feb 2;359(6375):550-555
pubmed: 29217587
Nature. 2014 Sep 18;513(7518):422-425
pubmed: 25043003
Science. 2018 Nov 23;362(6417):911-917
pubmed: 30337457
Science. 2020 Oct 2;370(6512):75-82
pubmed: 33004514
Dev Biol. 2021 Jun;474:100-108
pubmed: 33484705
Nat Rev Genet. 2013 May;14(5):307-20
pubmed: 23594909
Trends Cancer. 2020 Jan;6(1):31-39
pubmed: 31952779
J Med Genet. 2008 Oct;45(10):622-31
pubmed: 18511569
Nature. 2018 Sep;561(7724):473-478
pubmed: 30185910
Fam Cancer. 2009;8(3):209-13
pubmed: 19130300
Science. 2019 Jun 07;364(6444):
pubmed: 31171663
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Am J Hum Genet. 1999 Jun;64(6):1632-7
pubmed: 10330349
Science. 2015 May 22;348(6237):880-6
pubmed: 25999502
JAMA Oncol. 2021 Dec 1;7(12):1800-1805
pubmed: 34709361
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Nat Genet. 2016 Feb;48(2):126-133
pubmed: 26656846
Nature. 2017 Mar 30;543(7647):714-718
pubmed: 28329761
Int J Cancer. 2014 Oct 15;135(8):1756-63
pubmed: 24945890
Nature. 2021 Sep;597(7876):393-397
pubmed: 34433967
Nature. 2021 Sep;597(7876):387-392
pubmed: 34433963
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821